2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
1
Active Trials
200 recruiting
3
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Amplia Therapeutics is a company with 2 orphan drug designations across 3 rare diseases. Active clinical trials in 1 indication.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| cancer | - | Des.TrialAppr. |
| idiopathic pulmonary fibrosis | Benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]- | Des.TrialAppr. |
| malignant pancreatic neoplasm | benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]- | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
23
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
23
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio